BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van de Ven M, Koffijberg H, Retèl V, Monkhorst K, Smit E, van Harten W, IJzerman M. Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals. J Mol Diagn 2021;23:484-94. [PMID: 33493663 DOI: 10.1016/j.jmoldx.2021.01.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Simons MJHG, Retèl VP, Ramaekers BLT, Butter R, Mankor JM, Paats MS, Aerts JGJV, Mfumbilwa ZA, Roepman P, Coupé VMH, Uyl-de Groot CA, van Harten WH, Joore MA. Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer. Pharmacoeconomics 2021. [PMID: 34405371 DOI: 10.1007/s40273-021-01073-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Simons M, Van De Ven M, Coupé V, Joore M, IJzerman M, Koffijberg E, Frederix G, Uyl-De Groot C, Cuppen E, Van Harten W, Retèl V. Early technology assessment of using whole genome sequencing in personalized oncology. Expert Rev Pharmacoecon Outcomes Res 2021;21:343-51. [PMID: 33910430 DOI: 10.1080/14737167.2021.1917386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wu Z, Huang X, Cai M, Huang P, Guan Z. Development and Validation of a Prognostic Index Based on Genes Participating in Autophagy in Patients With Lung Adenocarcinoma. Front Oncol 2022;11:799759. [DOI: 10.3389/fonc.2021.799759] [Reference Citation Analysis]